Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The impasse over US drug reimportation may be a blessing in disguise

This article was originally published in SRA

Executive Summary

The growth of expenditures on prescription drugs in the US is prompting consumers and policy makers to explore alternative routes to control drug spending. Senior citizens and uninsured people have been among the hardest-hit populations during the latest economic recession in particular and consumers have been forced to live with difficult choices. Some 15-25% of the population has reported not filling a prescription on time and/or reducing a prescribed dosage due to lack of affordability1,2.

You may also be interested in...



Washington State Ecology Mulls ‘Safer’ Definition While Exploring Phthalate Alternatives In Fragrances

Marissa Smith, senior regulatory toxicologist in the Washington Department of Ecology’s Hazardous Waste and Toxics Reduction program, discusses what’s next for the state’s inaugural Safer Products go-round. “How we define ‘safer’ is really going to be the lynchpin of this whole process,” she says.

COVID-19 Deter Class Actions? No. Plaintiffs' Attorneys Have Time For More Complaints? Yes.

Class action complaints filed in 2020 against food, dietary supplement and beverage firms should pass 2019’s total as COVID-19 has not slowed litigants but has given plaintiffs’ council more time out of court to shop for new cases.

Abbott Surprises Industry With CE Mark For Freestyle Libre 3

The new continuous glucose sensor is the smallest and thinnest in the world, according to Abbott.

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel